

IBC Meeting Minutes

Cleveland Clinic Florida Research and Innovation Center

Date: May 21, 2026	Location: Zoom
IBC Member Attendance:	
<input checked="" type="checkbox"/> McDonald, Christine (IBC Chair) <input type="checkbox"/> Li, Kun <input checked="" type="checkbox"/> Such, Kimberly <input checked="" type="checkbox"/> Champer, Dylan (Biosafety Officer) <input type="checkbox"/> Hajjar, Adeline <input checked="" type="checkbox"/> Judd, Leslie <input checked="" type="checkbox"/> Tavakoli, Sara <input checked="" type="checkbox"/> O'Connor, Christine <input checked="" type="checkbox"/> Doud, Melissa <input checked="" type="checkbox"/> Stolley, Michael	
<i>Guests: Amanda Dragan*, Anna Rietsch *, Anthony Santilli*, Jennifer Veillette*, Nikki Meyer*</i> <i>*Cleveland Clinic Main Campus</i>	
Call To Order: 2:35 pm	Adjourn: 2:53 pm

I. Review of April 16th, 2026 Meeting Minutes

Committee Comments: None			
Motion: Approval	For: 8	Against: 0	Abstain: 2

II. Administrative Business

- a. Committee presented with Subcommittee Review items and personnel additions.
- b. Lab Audits: Members were presented with and informed of Annual Lab Audits and Preliminary Audits occurring during the month of March 2026. No major deficiencies were identified.
- c. Incident Report: IBC Members were informed of an incident involving a BSL-1 biohazardous spill. The resulting risk assessments and corrective actions taken to prevent further occurrences were also presented.

III. Non-Clinical Research:

a. Amendments:

Basic Research Amendment # 1	Protocol ID: FLIBC001	PI: Gack	Biosafety Level: BSL-1, BSL-2, BSL-2+, ABSL-2	NIH Cat.: III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b, III-D-7, III-E
-------------------------------------	---------------------------------	--------------------	---------------------------------------------------------	--------------------------------------------------------------------------------

Project Titles: Regulation of Host Antiviral Innate Immunity					
Associated Grant Numbers: NIH (2023): 5DP1AI169444-03, 5R01 AI148534-04, 5R01 AI165502-03, 5 R37 AI087846-14, 1 R21 AI174534-01A1 ; Non-NIH Funding					
Summary of Approved Items: Propagation of recombinant and non-recombinant viruses, transduction of tissue culture cells, administration of viruses and viral transduced cells <i>in vivo</i> ; Generation and propagation of recombinant and wild type SARS-CoV-2 virus, infection of cell lines and experimental analyses, administration of recombinant and wild type SARS-CoV-2 virus <i>in vivo</i> ; Human-derived materials.					
Requested Additions/Changes: <ul style="list-style-type: none"> Addition of new administration route for in vivo procedures, addition of new in vivo procedures and overexpression of genes for hantavirus proteins. Addition of new ABSL1 space. 					
<u>Function/Nature of Recombinant Genes to be Expressed:</u> <input type="checkbox"/> N/A <input type="checkbox"/> Oncogene <input type="checkbox"/> Tumor Suppressor Gene <input type="checkbox"/> Structural <input type="checkbox"/> Signaling <input type="checkbox"/> Antimicrobial <input checked="" type="checkbox"/> Immunomodulatory <input type="checkbox"/> Toxin <input type="checkbox"/> Antibiotic Resistance <input type="checkbox"/> Reporters <input checked="" type="checkbox"/> Other					
<u>Species of Recombinant Genes to be Expressed:</u> <input type="checkbox"/> N/A <input type="checkbox"/> Human <input type="checkbox"/> Murine <input type="checkbox"/> Rat <input type="checkbox"/> Bacterial <input checked="" type="checkbox"/> Viral <input type="checkbox"/> Other					
Risk Assessment Discussion: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Facilities, Procedures, and Safety Practices Reviewed (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Discussion/Required Modifications: <ul style="list-style-type: none"> Include addition of new ABSL-1 space Administrative edits 					
PI/Supervisor Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Handler Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Motion: Approved with Administrative Revisions	For: 8	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0
Basic Research Amendment # 2	Protocol ID: FLIBC021	PI: Sautto	Biosafety Level: BSL-1, BSL-2+, ABSL-2	NIH Cat.: III-E, III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b	
Project Titles: Influenza and hepatitis C virus neutralization					

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:
Propagation and generation of Influenza A & B viral strains and recombinant Hepatitis C Virus, virus like particles / pseudoparticles; Transduction of tissue culture cells; Generation of phagemid and retroviral particles, transduction of cells in-vitro, administration of Influenza A & B viral strains, plasmid DNA, *in vivo*; Generation and propagation of Measles virus; Generation of Nipah pseudovirus; Recombinant and Non-Recombinant Respiratory syncytial virus and human metapneumovirus for in vitro and *in vivo* experiments; Propagation of SARS-CoV-2, *in vivo* administration of SARS-CoV-2, human-derived materials.

Requested Additions/Changes:

- Addition of RNA as a vaccination platform for HCV in vivo studies and imaging for RSV infection.

Function/Nature of Recombinant Genes to be Expressed:
 N/A Oncogene Tumor Suppressor Gene Structural Signaling Antimicrobial
 Immunomodulatory Toxin Antibiotic Resistance Reporters Other

Species of Recombinant Genes to be Expressed:
 N/A Human Murine Rat Bacterial Viral Other

Risk Assessment Discussion: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Facilities, Procedures, and Safety Practices Reviewed (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
-----------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------

Committee Comments:

- Administrative edits

PI/Supervisor Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Handler Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
-------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------

Motion: Approved with Administrative Revisions	For: 8	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0
-------------------------------------------------------------	------------------	----------------------	----------------------	---------------------	--------------------------

Basic Research Amendment # 3	Protocol ID: FLIBC015	PI: Thomas	Biosafety Level: BSL-2, BSL-2+	NIH Cat.: III-D-1-a
-------------------------------------	---------------------------------	----------------------	------------------------------------------	-------------------------------

Project Titles:
Sample preparation, cell sorting and flow-cytometric analysis of unfixed samples requiring BSL-2/BSL-2+ containment

Associated Grant Numbers:
Non-NIH Funding

Summary of Approved Items:

Sample preparation, cell sorting and flow cytometric analysis of fixed and unfixed samples containing Risk Group 2 / 2+ agents. All agent has to be approved by the IBC for each investigator, before use on Core equipment; Human derived materials.					
Requested Additions/Changes:					
<ul style="list-style-type: none"> Addition of new BSL-1 space 					
<u>Function/Nature of Recombinant Genes to be Expressed:</u>					
<input checked="" type="checkbox"/> N/A <input type="checkbox"/> Oncogene <input type="checkbox"/> Tumor Suppressor Gene <input type="checkbox"/> Structural <input type="checkbox"/> Signaling <input type="checkbox"/> Antimicrobial <input type="checkbox"/> Immunomodulatory <input type="checkbox"/> Toxin <input type="checkbox"/> Antibiotic Resistance <input type="checkbox"/> Reporters <input type="checkbox"/> Other					
<u>Species of Recombinant Genes to be Expressed:</u>					
<input checked="" type="checkbox"/> N/A <input type="checkbox"/> Human <input type="checkbox"/> Murine <input type="checkbox"/> Rat <input type="checkbox"/> Bacterial <input type="checkbox"/> Viral <input type="checkbox"/> Other					
Risk Assessment Discussion:			Facilities, Procedures, and Safety Practices Reviewed (Y/N):		
<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Committee Comments:					
<ul style="list-style-type: none"> None 					
PI/Supervisor Training (Y/N):			Handler Training (Y/N):		
<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Motion:	For:	Against:	Abstain:	Recuse:	Not Present:
Approved	8	0	0	0	0

IV. Updated SOPs:

a: L.SOP.201.05 - Autoclave Safe Use and Validation	Comments: Administrative edits				
Motion:	For:	Against:	Abstain:	Recuse:	
Approved with Administrative Revisions	8	0	0	0	
b: L.SOP.300.04 - Sharps - Safe Handling and Disposal	Comments: None				
Motion:	For:	Against:	Abstain:	Recuse:	
Approved	8	0	0	0	
c: L. MAN.101.03 Biological Safety Manual	Comments: None				
Motion:	For:	Against:	Abstain:	Recuse:	
Approved	8	0	0	0	